Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Liabilities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Total Liabilities for 13 consecutive years, with $656.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 128.2% to $656.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $656.9 million, a 128.2% increase, with the full-year FY2025 number at $656.9 million, up 128.2% from a year prior.
  • Total Liabilities was $656.9 million for Q4 2025 at Madrigal Pharmaceuticals, down from $736.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $736.7 million in Q3 2025 to a low of $49.2 million in Q1 2021.
  • A 5-year average of $233.3 million and a median of $207.3 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: grew 21.97% in 2024, then skyrocketed 148.8% in 2025.
  • Madrigal Pharmaceuticals' Total Liabilities stood at $77.2 million in 2021, then surged by 113.9% to $165.2 million in 2022, then soared by 42.4% to $235.2 million in 2023, then increased by 22.38% to $287.9 million in 2024, then skyrocketed by 128.2% to $656.9 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Total Liabilities are $656.9 million (Q4 2025), $736.7 million (Q3 2025), and $319.4 million (Q2 2025).